ArticleCancers2019
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 74 citations in OpenAlex.
- Choriocarcinoma: Diagnosis, treatment and management of a rare germ cell tumour. An update review.Tumori · 2026Review
- MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment.Frontiers in immunology · 2026Review
- Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors.Journal of cancer research and clinical oncology · 2025Article
- GRK5 as a Novel Therapeutic Target for Immune Evasion in Testicular Cancer: Insights from Multi-Omics Analysis and Immunotherapeutic Validation.Biomedicines · 2025Article
- Disparate Roles of Cell-Cell Contact and Cytokine Secretion in an In Vitro Model of the Seminoma Microenvironment.International journal of molecular sciences · 2025Article
- Immune cell profiling of peripheral blood in long-term testicular germ cell tumor survivors.Frontiers in immunology · 2025Article
- The clinical significance of T cell infiltration and immune checkpoint expression in central nervous system germ cell tumors.Frontiers in immunology · 2025Article
- Immune profiling of pediatric germ cell tumors identifies key cell populations and novel therapeutic targets.Frontiers in immunology · 2025Article
- Exploiting potential molecular compounds for treating testicular seminoma by targeting immune related genes.Cell communication and signaling : CCS · 2024Article
- The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.Current oncology (Toronto, Ont.) · 2024Review
- PD-L1 expression in testicular germ cell tumors undergoing spontaneous regression.Biomolecules & biomedicine · 2024Article
- The expression of programmed cell death ligand 1 (PD-L1) involves in the clinicopathologic characteristics and prognostic implications of testicular germ cell tumor (TGCT): a systematic review and meta-analysis.Translational cancer research · 2024Article
- The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors.Cancers · 2024Review
- Pure testicular choriocarcinoma, a rare and highly malignant subtype with challenging treatment: A case report and review of the literature.Molecular and clinical oncology · 2024Article
- Review
- Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.International journal of molecular sciences · 2023Review
- Identification of testicular cancer immune infiltrates and novel immune cell subtypes.FEBS open bio · 2023Article
- Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options.Molecular medicine (Cambridge, Mass.) · 2023Article
- Ovarian yolk sac tumor in a premenarchal girl.Wiener medizinische Wochenschrift (1946) · 2023Article
- Seminoma subtypes differ in the organization and functional state of the immune microenvironment.3 Biotech · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
João LoboDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. jpedro.lobo@ipoporto.min-saude.pt.ORCID 0000-0001-6829-1391
Ângelo RodriguesDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. angelorod57@gmail.com.
Rita GuimarãesDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. ritaguimaraes.apct@gmail.com.
Mariana CantanteDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. marianacantantecf@gmail.com.
Paula LopesDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. lopesanapaula.s@gmail.com.
Joaquina MaurícioDepartment of Medical Oncology & Urology Clinic, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. jmauricio@ipoporto.min-saude.pt.
Jorge OliveiraDepartment of Urology & Urology Clinic, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. urojorge@gmail.com.
Carmen JerónimoCancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt.ORCID 0000-0003-4186-5345
Rui HenriqueDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. henrique@ipoporto.min-saude.pt.ORCID 0000-0003-3171-4666
Instituto Português de Oncologia Francisco Gentil · PTUniversidade do Porto · PT
Funding
Fundação para a Ciência e a Tecnologia PTDC/MECONC/ 29043/2017Fundação para a Ciência e a Tecnologia SFRH/BD/132751/2017
Abstract
PubMed holds no abstract for this paper.
Indexed as
CTLA-4immune checkpointsmismatch repairPD-L1prognosissurvivaltesticular germ cell tumors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.